Anam M. Khan, PhD

Research Epidemiologist
RTI Health Solutions, United States

Disclosure information not submitted.

Presentation(s):

• 4C-06 - Evolution of Drug Initiation Patterns and Clinical Characteristics of New Users of Dapagliflozin in the United States up to 10 Years After Approval to Treat Type 2 Diabetes

  Monday, August 25, 2025
  5:30 PM - 5:45 PM ET